In December of 2021, Ann Arbor Pharmacometrics Group (A2PG) joined forces with Amador Bioscience to strengthen its global leadership in clinical pharmacology. Together the companies have built an exciting and uniquely integrated solution for translational and early clinical development. As a one-stop provider, Amador now takes a unique position in the market as an integrated solution architect for CRO services across the lifecycle of drug development, from discovery to regulatory approval.
Over the last several months our partnership with A2PG has led to a successful global expansion of our clinical pharmacology business. Today, Amador is taking its partnership with A2PG one step further and fully integrating their expertise into the Amador services umbrella.
As part of this integration, Amador is making important changes to create a more unified leadership team and centralized structure for business development and client engagement.
Moving forward, Dr. Nidal Huniti, President of A2PG, will report directly to Dr. Bing Wang, CEO of Amador Bioscience. Additionally, Dr. Wonkyung Byon, Sr. Vice President at A2PG, and Dr. Nancy Dolphin, Executive Director, Medical Writing at A2PG will report to Dr. Huniti.
Amador regrets to report that the current CEO of A2PG, Dr. Sunny Chapel, will be leaving the company effective September 12, 2022. Amador thanks Dr. Chapel for her contributions to its successful start as a one-stop solution for nonclinical, early-, and late-stage clinical development services. We wish Dr. Chapel the best.
With this new leadership structure in place, the leadership team’s direct collaboration will further accelerate the unique offering of Amador Bioscience and A2PG and will drive us into the next phase of our end-to-end integrated solution architect expansion.